Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.35 |
| ▸ | CALCR | P30988 | 5/20 | 0.35 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29630744 | 0.92 | MAPK8 (0.50) | MAPK8MAPK9MAPK10KEAP1CALCRL | |
| SCHEMBL29531747 | 0.90 | KEAP1 (0.45) | MAPK8MAPK9MAPK10KEAP1CALCRL | |
| SCHEMBL30297942 | 0.87 | MAPK8 (0.47) | MAPK8MAPK9MAPK10KEAP1CALCRL | |
| SCHEMBL29980620 | 0.85 | PRCP (0.39) | MAPK8MAPK9MAPK10KEAP1CALCRL | |
| SCHEMBL29548137 | 0.85 | PRCP (0.41) | KEAP1PRCP | |
| SCHEMBL29924267 | 0.85 | PRCP (0.41) | KEAP1PRCP | |
| SCHEMBL30974174 | 0.84 | KDM1A (0.38) | MAPK8MAPK9MAPK10KEAP1KDM1A | |
| SCHEMBL31122253 | 0.84 | CALCRL (0.45) | MAPK8MAPK9MAPK10KEAP1CALCRL | |
| SCHEMBL30938813 | 0.83 | GHSR (0.40) | KEAP1KDM1AMAOBKDM5AKDM1B | |
| SCHEMBL30686002 | 0.83 | MAPK8 (0.42) | MAPK8MAPK9MAPK10KEAP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | MAPK8 4244/4885MAPK9 3429/4885MAPK10 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.